Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET plus MTC)

被引：24
|
作者：
Hu, M. [1 ]
Subbiah, V. [2 ]
Wirth, L. J. [3 ]
Schuler, M. [4 ,5 ]
Mansfield, A. S. [6 ]
Brose, M. S. [7 ]
Curigliano, G. [8 ,9 ,10 ]
Leboulleux, S. [11 ]
Zhu, V. W. [12 ]
Keam, B. [13 ]
Matos, I. [14 ]
Lin, C-C. [15 ]
Adkins, D. [16 ]
Baik, C. S. [17 ]
Lopes, G. [18 ]
Godbert, Y. [19 ]
Sarker, D. [20 ]
Zhang, H. [21 ]
Turner, C. [21 ]
Taylor, M. [22 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Invest Canc Therapeut, Houston, TX 77030 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA
[4] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[5] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany
[6] Mayo Clin, Div Med Oncol, Rochester, MN USA
[7] Univ Penn, Abramson Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA
[8] IRCCS, Dept Oncol, European Inst Oncol, Milan, Italy
[9] IRCCS, Dept Hematooncol, European Inst Oncol, Milan, Italy
[10] Univ Milan, Milan, Italy
[11] Gustave Roussy, Med Nucl & Endocrine Oncol, Villejuif, France
[12] Univ Calif Irvine, Dept Med, Orange, CA 92668 USA
[13] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
[14] Vall dHebron Inst Oncol, Early Drug Dev Unit, Barcelona, Spain
[15] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[16] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[17] Univ Washington, Sch Med, Thorac Head & Neck Med Oncol, Seattle Canc Care Alliance, Seattle, WA USA
[18] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[19] Bergonie Inst Canc Ctr, Nucl Med, Bordeaux, France
[20] Kings Coll London, Dept Med Oncol, Guys Hosp, London, England
[21] Blueprint Med Corp, Cambridge, MA USA
[22] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1401
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1913O
引用
收藏
页码：S1084 / S1084
页数：1
相关论文
共 45 条
  • [21] Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial
    Drilon, Alexander
    Subbiah, Vivek
    Gautschi, Oliver
    Tomasini, Pascale
    de Braud, Filippo
    Solomon, Benjamin J.
    Tan, Daniel Shao-Weng
    Alonso, Guzman
    Wolf, Juergen
    Park, Keunchil
    Goto, Koichi
    Soldatenkova, Victoria
    Szymczak, Sylwia
    Barker, Scott S.
    Puri, Tarun
    Bence Lin, Aimee
    Loong, Herbert
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 385 - +
  • [22] Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial
    Wirth, Lori J.
    Robinson, Bruce
    Boni, Valentina
    Tan, Daniel S. W.
    McCoach, Caroline
    Massarelli, Erminia
    Hess, Lisa M.
    Jen, Min-Hua
    Kherani, Jennifer
    Olek, Elizabeth
    Subbiah, Vivek
    ONCOLOGIST, 2022, 27 (01): : 13 - 21
  • [23] Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO-292)
    Wirth, L. J.
    Robinson, B.
    Boni, V.
    Tan, D. S. W.
    McCoach, C.
    Massarelli, E.
    Hess, L. M.
    Huang, X.
    Kherani, J. F.
    Olek, E.
    Subbiah, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S1089 - S1089
  • [24] Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial (vol 27, pg 13, 2022)
    Wirth, Lori J.
    Robinson, Bruce
    Boni, Valentina
    Tan, Daniel S. W.
    McCoach, Caroline
    Massarelli, Erminia
    Hess, Lisa M.
    Jen, Min-Hua
    Kherani, Jennifer
    Olek, Elizabeth
    Subbiah, Vivek
    ONCOLOGIST, 2022, 27 (12): : E982 - E982
  • [25] Relationship between RET fusion partner and treatment outcomes in patients (pts) with non-small cell lung cancer (NSCLC) from the phase I/II ARROW study and real-world data (RWD)
    Gadgeel, S. M.
    Gainor, J.
    Cappuzzo, F.
    Garralda, E.
    Lee, D. H.
    Mazieres, J.
    Kim, D-W.
    Zhu, V.
    Lopes, G.
    Miller, S.
    Nowicka, M.
    Trinh, H.
    Arndorfer, S. M.
    Rahman, A.
    Noe, J.
    Zhang, Q.
    Subbiah, V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1001 - S1002
  • [26] Efficacy and safety of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC): Results from a multicenter, single-arm, phase II study
    Xiong, Anwen
    Li, XingYa
    Yang, Nong
    Meng, Xiangjiao
    Yu, Qitao
    Tan, Liping
    Wang, Qiming
    Wang, Yongsheng
    Liu, Baogang
    Luo, Hui
    Wang, Ying
    Huang, Dingzhi
    Zhang, Yiping
    Song, Zhengbo
    Ye, Feng
    Fang, Jian
    Zhao, Mingfang
    Wang, Yongsheng
    Sun, Yinghui
    Zhou, Caicun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK plus ) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial
    Solomon, B. J.
    Drilon, A.
    Lin, J. J.
    Bazhenova, L.
    Goto, K.
    De langen, J.
    Kim, D-W.
    Wolf, J.
    Springfeld, C.
    Popat, S.
    Lim, D. W-T.
    Baik, C. S.
    Hervieu, A.
    Garcia, V. Moreno
    Yang, N.
    Thamake, S.
    Ades, F.
    Trone, D.
    Besse, B.
    ANNALS OF ONCOLOGY, 2023, 34
  • [28] Evaluation of safety, tolerability, pharmacokinetics (PK) and efficacy of dabrafenib and trametinib combination (Dab plus Tra) therapy in Japanese patients (pts) with BRAF V600 mutation-positive advanced cutaneousmelanoma: a phase (Ph) I/II study
    Tsutsumida, A.
    Yamazaki, N.
    Takahashi, A.
    Namikawa, K.
    Fujiwara, Y.
    Kondo, S.
    Yoshikawa, S.
    Yoshino, Y.
    Suzuki, A.
    Mukaiyama, A.
    Nishimura, Y.
    Kiyohara, Y.
    ANNALS OF ONCOLOGY, 2015, 26 : 103 - 103
  • [29] Phase I high-dose trial of I-13 I-labeled MN-14 F(ab)(2) anti-CEA MAb combined with autologous bone marrow support in patients (PTs) with advanced medullary thyroid cancer (MTC).
    Juweid, M
    Sharkey, RM
    Swayne, LC
    Alexander, S
    Dunn, R
    Rubin, A
    Herskovic, T
    Goldenberg, DM
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 168 - 168
  • [30] First-Line Erlotinib vs Gemcitabine/Carboplatin (GC) in Activating EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Efficacy and Safety Results from Phase III OPTIMAL Study in Chinese Patients (pts)
    Wang, Chang-Li
    Zhou, Caicun
    Wo, Yi-Long
    Lu, Shun
    Zhang, Li
    Zhang, Yiping
    Ye, Ming
    Ma, Jun
    Huang, Jianan
    Xiu, Quingyu
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S373 - S374
12345